Sangamo Therapeutics (NASDAQ:SGMO) Research Coverage Started at StockNews.com

Equities researchers at StockNews.com started coverage on shares of Sangamo Therapeutics (NASDAQ:SGMO) in a research report issued to clients and investors on Saturday. The firm set a “sell” rating on the biopharmaceutical company’s stock.

SGMO has been the subject of a number of other research reports. HC Wainwright reiterated a “buy” rating and issued a $5.00 price objective (up previously from $3.00) on shares of Sangamo Therapeutics in a research report on Tuesday, March 19th. Royal Bank of Canada reissued a “sector perform” rating and issued a $2.00 target price on shares of Sangamo Therapeutics in a report on Thursday, March 14th. Two investment analysts have rated the stock with a sell rating, three have assigned a hold rating and three have given a buy rating to the company. Based on data from MarketBeat, Sangamo Therapeutics has a consensus rating of “Hold” and an average target price of $4.93.

Sangamo Therapeutics Trading Up 2.9 %

Shares of SGMO stock opened at $0.52 on Friday. The stock has a 50 day moving average of $0.77 and a two-hundred day moving average of $0.59. Sangamo Therapeutics has a 12 month low of $0.29 and a 12 month high of $1.78. The company has a market capitalization of $107.44 million, a P/E ratio of -0.35 and a beta of 1.39.

Sangamo Therapeutics (NASDAQ:SGMO) last announced its quarterly earnings data on Wednesday, March 13th. The biopharmaceutical company reported ($0.34) EPS for the quarter, missing analysts’ consensus estimates of ($0.25) by ($0.09). Sangamo Therapeutics had a negative return on equity of 82.17% and a negative net margin of 146.30%. The firm had revenue of $2.04 million during the quarter, compared to the consensus estimate of $8.96 million. Sell-side analysts predict that Sangamo Therapeutics will post -0.54 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Sangamo Therapeutics

A number of hedge funds and other institutional investors have recently bought and sold shares of SGMO. Miracle Mile Advisors LLC acquired a new stake in Sangamo Therapeutics during the 3rd quarter valued at $25,000. Vanguard Personalized Indexing Management LLC acquired a new stake in shares of Sangamo Therapeutics in the 3rd quarter valued at $26,000. Mackenzie Financial Corp increased its stake in shares of Sangamo Therapeutics by 72.4% in the 4th quarter. Mackenzie Financial Corp now owns 73,799 shares of the biopharmaceutical company’s stock valued at $40,000 after buying an additional 31,003 shares during the period. SG Americas Securities LLC increased its stake in shares of Sangamo Therapeutics by 255.2% in the 3rd quarter. SG Americas Securities LLC now owns 88,542 shares of the biopharmaceutical company’s stock valued at $53,000 after buying an additional 63,612 shares during the period. Finally, Golden State Equity Partners increased its stake in shares of Sangamo Therapeutics by 22.5% in the 3rd quarter. Golden State Equity Partners now owns 166,265 shares of the biopharmaceutical company’s stock valued at $100,000 after buying an additional 30,500 shares during the period. 56.93% of the stock is owned by institutional investors and hedge funds.

Sangamo Therapeutics Company Profile

Sangamo Therapeutics, Inc, a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A; BIVV003, a zinc finger nuclease gene-edited cell therapy product candidate that is in Phase 1/2 PRECIZN-1 clinical study for the treatment of sickle cell disease.